From obesity to renal disease, chronic conditions remain some of the toughest challenges in veterinary medicine. Changemakers examine how next-generation therapeutics, supported by diagnostics and other modalities, can deliver sustainable results and change the way veterinarians manage long-term disease.
Zoetis
Website: https://www.zoetis.com/
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees.
For more information, visit www.zoetis.com
From generics to distribution partnerships, new routes to market are widening access and reshaping the competitive landscape. Leaders share how these pathways are driving scale, lowering barriers, and creating new opportunities in animal health.
- Innovation in commercialisation
- Innovation in value
- Innovation in routes to market
Panellists
Steve Shell
President
MWI Animal Health
From prevention to treatment, animal health companies are rethinking how products and services connect across the care journey. Industry leaders will discuss how integration is reshaping delivery models, improving outcomes, and setting new benchmarks for the continuum of care.
- Building a sustainable competitive advantage through customer centricity
- Applications of AI & Data that fundamentally change the pet owner experience
- Practice workflows, service models and reaching the animal
Panellists
Jesper Nordengaard
CEO
Dechra
Gudrun Ravetz
Group Chief Medical Officer
IVC Evidensia
Currently Gudrun works as a Veterinary Consultant to Pet Health Plans from Denplan and as an external interviewer for prospective veterinary students at University of Liverpool. Alongside practicing as a small animal veterinary surgeon on graduating in 2002, Gudrun furthered her interest in the business side of the veterinary profession by studying for the post graduate certificate in business. Gudrun became President at the BVA Member’s Day and AGM on 22 September 2016.
Transboundary animal diseases (TADs) such as avian influenza, bluetongue virus, and foot-and-mouth disease pose serious risks to animal health, livestock production, and public health. Past outbreaks have exposed gaps in disease awareness and preparedness, with farmers often bearing the greatest impact. Effective prevention, through international collaboration, biosecurity, vaccination, and surveillance, requires coordinated action to stop the spread and support eradication efforts.
Panellists
Pascal Hudelet
Head of Global Technical Service, Veterinary Public Health (VPH) Center
Boehringer Ingelheim
Boehringer Ingelheim
Website: https://www.boehringer-ingelheim.com/
Boehringer Ingelheim is among the world’s 15 leading pharmaceutical companies. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need for both humans and animals. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments.
Learn more at www.boehringer-ingelheim.com.